NCT02853942

Brief Summary

Main purpose:In the face of listening to nerve injury at early stage, utilizing autologous adipose stem cell transplantation in the treatment of makes the acceptance micro vascular decompression hemifacial spasm patients to nerve function to obtain a better recovery. Secondary purpose :To clarify the efficacy of stem cells in the treatment of cranial nerve dysfunction, and to provide evidence for the treatment of other cranial nerve dysfunction. Cases in group:Appearing on the surface of microvascular decompression for hemifacial spasm to decrease neural electrophysiological index of patients research design:Single center, prospective, randomized, double-blind, controlled Observation index:Facial nerve clinical score, facial nerve muscle compound action potential, electrical measurement, cerebrospinal fluid index Evaluation of therapeutic effect:Facial nerve function evaluation (House-Brackmann classification, facial nerve function classification scale SFGS), facial nerve electrophysiology evaluation (facial nerve muscle compound action potential), electric measurement Safety evaluation:Clear evaluation of hemifacial spasm and micro vascular decompression were listening to nerve in intracranial segment wrapped around the autologous fat stem cell therapy overall safety and evaluation methods including adverse events, laboratory tests, vital signs, electrocardiogram.

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
100

participants targeted

Target at P75+ for early_phase_1

Timeline
Completed

Started Oct 2016

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

July 14, 2016

Completed
20 days until next milestone

First Posted

Study publicly available on registry

August 3, 2016

Completed
2 months until next milestone

Study Start

First participant enrolled

October 1, 2016

Completed
1 year until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 1, 2017

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2017

Completed
Last Updated

August 9, 2016

Status Verified

August 1, 2016

Enrollment Period

1 year

First QC Date

July 14, 2016

Last Update Submit

August 7, 2016

Conditions

Outcome Measures

Primary Outcomes (1)

  • House-Brackmann facial nerve grading scale

    up to 3 months

Study Arms (2)

Stem cell therapy group

EXPERIMENTAL

Using the international standard 14G (diameter 1.54mm) needle inject autologous adipose derived mesenchymal stem cells 2ml to facial nerve, the effective release of the concentration is 100 million stem cells / ml.

Biological: Autologous adipose stem cell therapyDrug: Mecobalamin

Neurotrophic drugs treatment group

EXPERIMENTAL

Patients were treated with routine drug therapy,do not inject stem cell to the facial nerve of patient

Drug: Mecobalamin

Interventions

Stem cell therapy group
Neurotrophic drugs treatment groupStem cell therapy group

Eligibility Criteria

Age18 Years - 80 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • the age of 18 \~ 80 years old;
  • no surgical contraindications, accept facial nerve microvascular decompression surgery;
  • to enter into the group's informed consent and sign the consent form for clinical research.
  • patients with preoperative facial nerve electrophysiology examination without facial paralysis
  • patients with preoperative electrical testing without hearing impairment

You may not qualify if:

  • patients with poor compliance;
  • major surgical complications and interruption of treatment;
  • brain magnetic resonance examination or blood test results abnormal and clinical significance;
  • clinical trials of other drugs within 30 days;
  • the unintended side effects;

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Facial Nerve Injuries

Interventions

mecobalamin

Condition Hierarchy (Ancestors)

Facial Nerve DiseasesMouth DiseasesStomatognathic DiseasesCranial Nerve InjuriesCranial Nerve DiseasesNervous System DiseasesCraniocerebral TraumaTrauma, Nervous SystemWounds and Injuries

Study Design

Study Type
interventional
Phase
early phase 1
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Office of clinical research of Xinhua Hospital, Shanghai Jiao Tong University School of Medicine

Study Record Dates

First Submitted

July 14, 2016

First Posted

August 3, 2016

Study Start

October 1, 2016

Primary Completion

October 1, 2017

Study Completion

December 1, 2017

Last Updated

August 9, 2016

Record last verified: 2016-08

Data Sharing

IPD Sharing
Will share